Search for: "Vincent Joralemon"
Results 1 - 13
of 13
Sorted by Relevance
|
Sort by Date
13 Sep 2023, 5:00 am
Vincent Joralemon is a law student (J.D. 2024) in the Berkeley-Harvard Exchange Program. [read post]
27 Mar 2024, 5:40 pm
By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. [read post]
8 Apr 2009, 10:00 am
Checks can also be dropped off at Brooklyn Borough Hall or at the offices of Council Member Vincent Gentile. [read post]
8 Sep 2015, 1:58 pm
The exhibit will be open to the public on the first floor of Brooklyn Law School, 250 Joralemon Street from September 14th to 19th. [read post]
6 Oct 2023, 4:00 am
By Vincent Joralemon Psychedelics hold immense potential to address an array of conditions that are otherwise challenging to treat, but accessing these therapies can be costly, which means that potential benefits will be stratified along the lines of socioeconomic status. [read post]
12 Mar 2024, 5:00 am
By Vincent Joralemon The U.S. [read post]
4 Mar 2024, 5:00 am
By Vincent Joralemon Psychedelic companies and advocacy groups are spending substantial resources to influence regulatory policy, shaping what the blossoming field will ultimately cohere into. [read post]
19 Mar 2024, 5:00 am
By Vincent Joralemon MDMA (also known as the club drug “molly” or “ecstasy”) is a Schedule I controlled substance — the most restrictive drug class with the most severe criminal consequences linked to it. [read post]
26 Jan 2024, 5:00 am
By Vincent Joralemon There is little consensus in defining “psychedelic. [read post]
29 Nov 2023, 5:00 am
By Vincent Joralemon Spravato, the first FDA-approved psychedelic therapy, just outsold Viagra. [read post]
25 Oct 2023, 10:58 am
By Vincent Joralemon A $70 million deal struck between a venture capital firm and a prominent psychedelic advocacy organization suggests that funding for psychedelic research may increasingly rely on nonprofit and commercial partnerships. [read post]
7 Mar 2024, 5:00 am
By Vincent Joralemon In my last post, I discussed the rise of psychedelic lobbying — how companies with vested economic interests in psychedelics have applied pressure to shape regulations that favor their business models. [read post]
8 Nov 2023, 5:00 am
By Vincent Joralemon Psychedelics have a public relations problem, due in part to overzealous promoters, genuine risks, and bad science. [read post]
